Measures of health-related quality of life (HRQOL) in chronic esophageal conditions such as gastroesophageal refl ux disease, eosinophilic esophagitis, and achalasia are widely used to measure this important patient-reported outcome. We seek to leverage these existing measures to create a hybrid measure of esophageal illness HRQOL (the Northwestern Esophageal Quality of Life-NEQOL), allowing for broad use across diseases while maintaining sensitivity to nuances of a specifi c condition.
INTRODUCTION
Esophageal disorders, ranging from gastroesophageal refl ux disease (GERD), which aff ects up to 1/3 of the population ( 1 ), to less common but still prevalent conditions such as achalasia, eosinophilic esophagitis (EoE), Barrett's esophagus, and dysphagia, are associated with signifi cant disease burden, disability, and cost (2) (3) (4) . Health-related quality of life (HRQOL) is a multidimensional construct that captures the physical, mental, social, and emotional aspects of a patient's life and how health status impacts these domains. HRQOL can be readily measured through patient self-report and correlates with outcomes in a wide range of digestive diseases (5) (6) (7) (8) (9) . Th ere are two approaches to the measurement of HRQOL-generic and disease specifi cwith pros and cons to each approach ( 10 ) . Generic measures such as the MOS Short Form 36 (SF-36) or National Institutes for Health (NIH) Patient Reported Outcomes Measurement Information System (PROMIS) are useful because they allow for comparison of HRQOL across disease groups (e.g., GERD vs. diabetes) and against the general population. Disease-specifi c tools are also useful in that they yield important nuances around QOL in the esophageal population that would not otherwise be detected.
Disease-specifi c HRQOL measures exist for GERD ( 11, 12 ) , achalasia ( 13 ) , eosinophilic esophagitis ( 7 ), dysphagia ( 14 ) , and Barrett's esophagus ( 15 ) but are not without limitation-one major concern is that the existing measures combine severity of disease with social/emotional impact, making it diffi cult to isolate the true impact of disease on HRQOL, as severe symptoms do not necessarily correlate with worsened quality of life ( 8, 16 ) . Th e second major concern about existing esophageal measures is that most of them are not transportable across clinical and research settings due to length, ineffi ciency of administration (e.g., having to give a diff erent questionnaire to each presenting group), or they lack the complexity preferred by either the researcher or the clinician.
Our aim was to develop an easy-to-use, valid measure of esophageal HRQOL that addresses many of the existing concerns: (1) expeditiously and suffi ciently captures its important domains specifi c to esophageal conditions; (2) delineates HRQOL from disease-specifi c symptom severity, and (3) can be used more broadly across diseases of the esophagus.
MATERIALS AND METHODS

Scale Development and Data Collection
Following recommended guidelines for patient-reported outcome (PRO) measures development (FDA, 2009) ( 17 ) , this study consisted of a three-step process for patient-reported outcome development ( Figure 1 ).
Step 1 . Existing measures of HRQOL for GERD, dysphagia, achalasia, EoE, and Barrett's esophagus were reviewed for content by three study investigators (TT, LK, and JP): Gastrointestinal Quality of Life Index ( 18 ) , Quality of Life in Refl ux and Dyspepsia Patients ( 19 ) , GERD Analyzer ( 20 ) , GERD Assessment Scales ( 21 ), Nepean Dyspepsia Index ( 22 ) , MD Anderson Dysphagia Inventory ( 23 ), Laryngopharyngeal Refl ux HRQOL scale ( 24 ) , Refl ux-QUAL ( 25 ), Eosinophilic Esophagitis QOL-A ( 7 ), Achalasia QOL ( 13 ) , and the GERDQ ( 26 ) . Relevant themes related to HRQOL were identifi ed, and items from each questionnaire grouped by theme. Next, items were evaluated for redundancy, quality, ease of understanding, and relevance to the HRQOL construct. Items that were deemed to be poor quality, diffi cult to understand, or not relevant to the HRQOL construct (i.e., symptom rating questions) were removed. Th e study investigators' recommendations were compared for consensus.
Step 2 . Th e preliminary measure was given to a representative sample of patients with a confi rmed diagnosis of GERD, Barrett's esophagus, EoE, achalasia, or dysphagia of unknown etiology for a minimum of 6 months. Participants between the ages of 18 and 70 were recruited from a university-based outpatient gastroenterology practice and via a research dedicated website ( www.researchmatch.org ). Aft er informed consent was obtained, participants completed a series of online questionnaires:
Inclusion/Exclusion Screening . Esophageal diagnosis, GI comor bidity (e.g., irritable bowel syndrome, infl ammatory bowel disease, or other GI condition), serious mental illness (e.g., schizo phrenia and bipolar disorder), or other chronic illness was recorded. Patients who did not report an esophageal condition or had medical or mental health co-morbidity were excluded from the study to eliminate potential HRQOL confounders related to other conditions. Demographic and Clinical Information . Gender, age, race, ethnicity, education, income, geographic region of U.S., hometown population, misdiagnosis status (yes/no), number of outpatient GI visits in past year, number of current GI medications, use of dietary treatment, use of dietitian, number of endoscopic procedures in past year, use of therapist/counselor for GI illness, treatment adherence over past week rating (0-100), symptom severity rating (0-10), symptom expectation rating (0-10), symptom control rating (0-10), treatment effi cacy rating (0-10), treatment satisfaction rating (0-10), physician satisfaction rating (0-10). coded from 0 to 4, and a total score is obtained by summing all items.
Northwestern Esophageal Quality of Life Scale (NEQOL
Centers for Disease Control (CDC) Healthy Days HRQOL Scale .
Th e Centers for Disease Control healthy days is a standard measure of HRQOL ( 27 ) . Th e measure contains three modules that may all be used or be used individually: 4-item core module, 5-item activity limitations module, and 5-item healthy days symptom module. For this study, the core and symptom modules were used. ( 28 ) . Th e IIS is a 9-item measure of the degree of psychosocial impact of an illness. Questions are answered on a 4-point Likert scale from not at all to fully. Scores range from 0 to 27 with higher scores denoting a greater negative impact. Th e IIS demonstrates good reliability (α =0.88 to 0.93) and validity. ( 29 ) . The NIH PROMIS scales are validated measures of psychological distress. The anxiety scale contains seven items and the depression scale contains eight items on a 5-point Likert scale (never to always). Higher scores indicate greater anxiety and depression. Aft er completing the study, participants had the option to provide contact information to participate in the test-retest portion of the study approximately 2 weeks aft er completing the questionnaires. Th ose who opted to participate were sent the NEQOL to complete a second time within 14 days of completing step 2. Duration between time 1 and time 2 was recorded, as well as any changes to treatment and general ratings of symptom severity and control on a 10-point scale that were also collected at fi rst administration of the NEQOL.
Impact of Illness Scale (IIS)
NIH PROMIS Anxiety and Depression Scales
Step 3 . Aft er initial reliability analyses, validity, principle components factor analysis, and item reduction were completed on the preliminary NEQOL, we conducted cognitive interviews with patients in order to verify comprehension and rele vance of the NEQOL questions. Individuals aged 18-70 with a confi rmed diagnosis via medical record of GERD, Barrett's eso phagus, achalasia, dysphagia NOS, and eosinophilic esophagitis for at least 6 months were recruited. Individuals were invited to participate during an outpatient visit to the gastroenterology clinic, or over the phone, by a graduate student in clinical psychology (AB). Participants completed a phone pre-screen for exclusion criteria above then came in to the Division of Gastroenterology Academic Offi ces for an individual study session. Aft er providing consent, participants answered demographic questions and then participated in an audio-recorded interview. During the interview, they responded to the NEQOL items and answered follow-up questions to determine item comprehension and overall quality of the measure.
Statistical analysis
Data from the online system for step 2 were exported into SPSS v.22 for analyses. Preliminary descriptive statistics evaluated the data for normal distribution. Reliability of the NEQOL was evaluated via Cronbach alpha and the Guttman statistic for split-half reliability. Validity was measured by correlations with established HRQOL measures (Centers for Disease Control Healthy Days and IIS) and measures of psychological distress (NIH PROMIS). Principle components factor analysis with Varimax rotation evaluated the factor structure of the NEQOL. Inter-item correlations were evaluated with cutoff scores set for r >0.80 or <0.20 to indicate items for potential removal from the questionnaire. Test-retest reliability was evaluated with Pearson's correlations between time 1 and time 2 of the NEQOL administration. Paired samples t -tests evaluated any changes in NEQOL scores, illness severity, and symptom control between assessment periods, and independent samples t -tests evaluated differences in NEQOL scores for participants who made treatment adjustments compared with those without adjustments.
Individual interviews for step 3 were transcribed for content analysis. For each participant, survey items were classifi ed as clear or confusing. Following analysis of all items, a tally was made in order to determine which items were clear and straight-forward to everyone and which were confusing to many or some participants. Participants were asked whether any changes should be made to the items, and those suggestions were noted. Ceiling and fl oor eff ects were examined by determining whether greater than or equal to 80% of participants answered not at all true or very true to items. Each item was individually presented to study investigators with interview feedback for item refi nement and reduction.
RESULTS
Step 1
Aft er review of existing disease-specifi c HRQOL measures, a total of 30 items were included in the initial NEQOL.
Step 2
Th ree hundred and eighty-seven potential participants visited the study website and completed screening questions. Of these, 4 were excluded for not having the proper esophageal diagnosis, 15 for not having their diagnosis for a minimum of 6 months, 103 for having a co-morbid GI diagnosis (e.g., infl ammatory bowel disease), and 17 for having a co-morbid serious mental illness ( n =139 excluded). Of participants who met the inclusion criteria ( n =240), 233 completed all study questionnaires (97% completion rate). Th e study sample was primarily non-Hispanic Caucasian, female, college educated, and recruited from online sources ( Table 1 ) . Th e most common diagnosis was GERD, followed by EoE and Achalasia. No signifi cant diff erences existed between recruitment sources (online versus clinic) for NEQOL scores ( P =0.90); hence, the entire sample was pooled for analyses.
Reliability analyses of the 30-item NEQOL yielded excellent internal consistency (Cronbach's α =0.96) and split-half reliability (Guttman statistic=0.94). Principle components factor analysis yielded a fi ve-factor structure; however, the majority of items fell on Factor 1 (eigenvalue=15.24). Inter-item correlations ESOPHAGUS VOLUME 111 | APRIL 2016
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indicated three items with poor correlations (<0.20), with most other items on the scale and three items with high inter-item correlations (>0.80) with at least one other question; fi ve of these items were subsequently removed from the scale. Th e item "I worry that I may develop esophageal cancer in the future" was retained based on study investigator opinion of the importance to capture this concern, especially among patients with Barrett's esophagus and achalasia. Study investigators (TT, LK, and JP) evaluated the remaining items for redundancy for further reduction or modifi cation. Th e intermediate version of the NEQOL subsequently contained 19 of the original 30 items to be evaluated via cognitive interviews.
Th e NEQOL demonstrated excellent construct validity, supported by strong positive correlations with the Centers for Disease Control healthy days, IIS, and the NIH PROMIS Scales ( Table 2 ) . Overall, moderate correlations existed (0.47-0.76), indicating separate yet related constructs. In addition, the NEQOL significantly correlated with disease-specifi c scores of illness severity (negative relationship) and with symptom control and treatment eff ectiveness (positive relationship; Table 2 ). HRQOL was also associated with poorer physician-patient relationship rating and lower treatment satisfaction.
Ninety-two participants completed the test-retest portion of the study. Of these, 69 (75%) reported no change in their esophageal treatment since the fi rst assessment. On average, participants rated their illness severity at 5.35(2.15) and their symptom control at 5.65(2.50) out of 10 over the previous 30 days. Test-retest reliability was above acceptable cutoff s ( r =0.88, P <0.001), indicating excellent temporal stability in NEQOL scores between administration points with a mean time between administrations of 32 days. A signifi cant decrease in self-rated illness severity existed between time 1 and time 2 (6.61 vs. 5.59, 
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Development of the Northwestern Esophageal Quality of Life Scale days ( P =0.02) but reported better HRQOL than those whose treatment remained stable ( P =0.03); illness severity did not change.
Step 3
A total of 15 people participated in the cognitive interviews. Th e sample consisted primarily of middle-aged, non-Hispanic Caucasians and was evenly distributed by gender ( Table 3 ). Most attained a college or a post-graduate education, and the majority were employed at a full or a part-time status. Th e majority were diagnosed with EoE and achalasia, with fewer diagnosed with GERD or dysphagia. We were unable to recruit any patient with Barrett's esophagus because available patients were either ineligible because of being over age 70 or had received corrective surgery and no longer had Barrett's esophagus. Overall, fi ve items described as vague, redundant, or demonstrating signifi cant fl oor eff ects were removed from the NEQOL resulting in a 14-item fi nal version (Appendix A). Other items were reworded based on participant feedback (i.e., Item 7, "I'm concerned eating will make me feel ill", the word "ill" was changed to "sick", because of ambiguity expressed by participants regarding the word "ill"; Item 12, "I avoid social activities that I once enjoyed" was modifi ed to say "I limit my social activities (e.g., hobbies, exercise, sex) because of my esophageal condition" in order to provide examples; Item 17, "I feel frustrated" was modifi ed to say "I feel angry or frustrated about my esophageal condition", in order to incorporate a range of emotions expressed by participants during the interviews.
DISCUSSION
We found the NEQOL to be a reliable and a valid measure of health-related quality of life in a large cohort of patients with GERD, EoE, achalasia, dysphagia, and Barrett's esophagus. Th is study took established disease-specifi c esophageal HRQOL measures and consolidated them into a 14-item survey that allows for rapid assessment in a clinical setting or cross-disease comparisions in a research study. Measures of internal consistency, splithalf reliability, test-retest reliability, and construct validity were at or above established guidelines for scale development.
Food and Drug Administration guidelines for the development of reliable and valid patient-reported outcomes outline a threephase paradigm to meet standards of acceptability: (1) initial qualitative inquiry with patients aff ected by the condition to guide question development, (2) administration of the measure to a suffi cient and a representative sample in order to conduct quantitative psychometric analyses, and (3) qualitative inquiry via cognitive interviews to ensure that feasibility, acceptability, and construct validity are suffi cient. Th is study follows Phases 2 and 3 of these guidelines. In lieu of Phase 1, the initial qualitative inquiry to inform question develop ment, established and validated questionnaires guided development of the initial questionnaire.
Th e development of the NEQOL as a "hybrid" measure between generic and disease-specifi c measures of HRQOL allows for broad use across diseases while maintaining sensitivity to the nuances of P <0.01); no signifi cant changes existed for symptom control and overall QOL. Participants who made treatment changes reported signifi cantly poorer symptom control over the past 30 Bedell et al.
symptoms of a specifi c disease. Hybrid measures, such as this one, have been developed in other health domains including chronic illness as a whole ( 30 ) , heart disease ( 31 ), and liver disease ( 32 ) . Th e NEQOL has the potential for both clinical and research utility; further validation is warranted in larger, more racially diverse samples and among conditions that were poorly represented in the current study (i.e., Barrett's esophagus). Th e NEQOL correlated with several disease-specifi c scores including self-reported symptom severity, symptom control, and general HRQOL. Poorer HRQOL was modestly correlated with increased esophageal symptoms, poorer symptom control, and reduced treatment eff ectiveness. Th ese fi ndings are similar to preexisting literature on the relationship between HRQOL and these patient outcomes (33) (34) (35) . In addition, patient satisfaction with treatment and their relationship with their physician were also negatively associated with HRQOL scores. Future studies should evaluate the NEQOL with other disease-specifi c measures of HRQOL such as the GERDQ and Achalasia QOL to confi rm these relationships.
Several limitations should be taken into consideration when interpreting our results. In part 2 of the study, the majority of patients were recruited online (82.4%), and therefore we were unable to confi rm their diagnosis. However, comparison of NEQOL scores between clinic and online sources demonstrated no signifi cant diff erences between groups. In addition, the sample was primarily Caucasian, non-Hispanic, and highly educated; hence, caution should be applied when using the NEQOL in diverse populations. Finally, as we were unable to recruit any patient with Barrett's esophagus for part 3, we should use caution when applying the NEQOL to this diagnosis group. As such, additional validation is recommended before it is fully ready for clinical or research purposes.
Th e NEQOL is designed as a rapid assessment tool of HRQOL in clinical settings. More detailed, disease-specifi c measures remain the preferred method of evaluating HRQOL for research purposes until the NEQOL is suffi ciently evaluated across multiple samples. For studies evaluating several esophageal disorders, use of the NEQOL versus generic measures of HRQOL has merit following further validation in more diverse samples. In summary, the NEQOL is an easy-to-use, valid measure of Esophageal HRQOL that addresses concerns related to existing measures, capturing domains specifi c to several diseases of the esophagus while delineating HRQOL from symptom severity.
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Study Highlights
WHAT IS CURRENT KNOWLEDGE
✓ Health related quality of life (HRQOL) correlates with outcomes in a wide range of digestive diseases and can be measured through patient self-report.
✓ Two types of HRQOL measures exist-generic and disease specifi c-and both have strengths and limitations.
✓ Generic measures allow for comparisons across disease groups but may overlook nuances of symptoms associated with particular conditions. ✓ Disease-specifi c measures exist for gastroesophageal refl ux disease (GERD), achalasia, eosinophilic esophagitis, achalasia, dysphagia, and Barrett's esophagus but have signifi cant limitations because of the inclusion of symptom severity, which does not always correlate with worsened quality of life.
WHAT IS NEW HERE
✓ The Northwestern Esophageal Quality of Life (NEQOL) is a "hybrid" measure between generic and disease-specifi c measures that allows for broad use across diseases while maintaining sensitivity to the nuances of symptoms of a specifi c disease.
✓ The NEQOL is a reliable and a valid measure of HRQOL that is easy to administer in clinical settings with potential utility in research.
